Association of proton‐pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta‐analyses of cohort studies and randomised controlled …
SK Veettil, S Sadoyu, EM Bald… - British Journal of …, 2022 - Wiley Online Library
Aims The aim was to perform an umbrella review to summarise the existing evidence on
proton‐pump inhibitor (PPI) use and adverse outcomes and to grade the certainty of …
proton‐pump inhibitor (PPI) use and adverse outcomes and to grade the certainty of …
[HTML][HTML] Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
Introduction Famotidine is a competitive histamine H2-receptor antagonist most commonly
used for gastric acid suppression but thought to have potential efficacy in treating patients …
used for gastric acid suppression but thought to have potential efficacy in treating patients …
[HTML][HTML] Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis
SB Israelsen, MT Ernst, A Lundh, LF Lundbo… - Clinical …, 2021 - Elsevier
Background & Aims Proton pump inhibitor (PPI) use has been associated with increased risk
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe …
Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: a randomized, double-blind, and placebo-controlled study
Objectives This is an investigation of the efficacy and safety of famotidine, a selective
histamine H2 receptor antagonist, on improvement of cognitive impairment, depression and …
histamine H2 receptor antagonist, on improvement of cognitive impairment, depression and …
[HTML][HTML] Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study …
S Yamate, C Ishiguro, H Fukuda, S Hamai… - Plos one, 2024 - journals.plos.org
Background Rebamipide has been widely co-prescribed with non-steroidal anti-
inflammatory drugs (NSAIDs) in Japan for decades. This study aimed to evaluate the …
inflammatory drugs (NSAIDs) in Japan for decades. This study aimed to evaluate the …
Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort
Provenance and peer review Not commissioned; internally peer reviewed. Supplemental
material This content has been supplied by the author (s). It has not been vetted by BMJ …
material This content has been supplied by the author (s). It has not been vetted by BMJ …
Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию
ДИ Трухан, ДС Иванова - Фарматека, 2022 - elibrary.ru
Лекарственная безопасность является одним из приоритетных направлений
современной медицины и фармации-прежде всего в аспекте рациональной …
современной медицины и фармации-прежде всего в аспекте рациональной …
Proton Pump Inhibitors and Risk of COVID-19 Infection in Children
S Hirsch, E Liu, R Rosen - The Journal of Pediatrics, 2024 - Elsevier
Objective To evaluate the influence of proton pump inhibitor (PPI) use on COVID-19
susceptibility and severity in children. Study design This retrospective, case-control study …
susceptibility and severity in children. Study design This retrospective, case-control study …
[HTML][HTML] A birds-eye (Re) view of acid-suppression drugs, COVID-19, and the highly variable literature
C Mura, S Preissner, R Preissner… - Frontiers in …, 2021 - frontiersin.org
This Perspective examines a recent surge of information regarding the potential benefits of
acid-suppression drugs in the context of COVID-19, with a particular eye on the great …
acid-suppression drugs in the context of COVID-19, with a particular eye on the great …
[HTML][HTML] Famotidina en el tratamiento de pacientes hospitalizados con COVID-19. Revisión sistemática y metaanálisis
JS Paisig Rosas… - Revista chilena de …, 2024 - SciELO Chile
Introducción: El síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2), de alta
morbimortalidad, carece a la fecha de preparar esta revisión, de una terapia específica …
morbimortalidad, carece a la fecha de preparar esta revisión, de una terapia específica …